Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
New Post
New Jersey federal court grants summary judgment in SEC’s insider trading case against former Apple exec
July 8, 2024
News Alert
Former NAPCO Comptroller settles with SEC to resolve insider trading charges
July 3, 2024
News Alert